Anebulo Pharmaceuticals, Inc.

Market Cap: N/A
Industry: Pharmaceuticals & Biotechnology
ISIN: US0345691036

USD

2.35

-0.03 (-1.26%)

Dec 04

NAS

Click here to see other stocks

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Pyxis Oncology, Inc.

SCYNEXIS, Inc.

CytomX Therapeutics, Inc.

Aquestive Therapeutics, Inc.

Chimerix, Inc.

aTyr Pharma, Inc.

GlycoMimetics, Inc.

Achieve Life Sciences, Inc.

Atossa Therapeutics, Inc.

Anebulo Pharmaceuticals, Inc.

Annovis Bio, Inc.

Why is Anebulo Pharmaceuticals, Inc. ?

Unrated Stock - No Analysis Available

Real-Time Research Report

Verdict Report

No Data Found

Is Anebulo Pharmaceuticals, Inc. for you?

High Risk, High Return

Absolute

Risk Adjusted

Volatility

Anebulo Pharmaceuticals, Inc.

51.61%

0.20

123.73%

S&P 500

13.22%

0.61

20.17%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

-100.00%

EBIT Growth (5y)

-215.15%

EBIT to Interest (avg)

-6.82

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.99

Sales to Capital Employed (avg)

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

55.78%

ROCE (avg)

ROE (avg)

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

3.30

EV to EBIT

-3.78

EV to EBITDA

-3.78

EV to Capital Employed

31.09

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

-823.30%

ROE (Latest)

-57.12%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Mildly Bearish

Mildly Bullish

RSI

No Signal

Bearish

Bollinger Bands

Sideways

Mildly Bullish

Moving Averages

Bullish (Daily)

KST

Mildly Bearish

Mildly Bullish

Dow Theory

Mildly Bearish

Mildly Bullish

OBV

No Trend

Mildly Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

7What is working for the Company

OPERATING CASH FLOW(Y)

Highest at USD -6.75 MM

NET PROFIT(HY)

Higher at USD -4.14 MM

RAW MATERIAL COST(Y)

Fallen by 0% (YoY

EPS(Q)

Highest at USD -0.04

-8What is not working for the Company

INTEREST(HY)

At USD 0.3 MM has Grown at 233.08%

Here's what is working for Anebulo Pharmaceuticals, Inc.

Net Profit

Higher at USD -4.14 MM

than preceding 12 month period ended Mar 2025

MOJO Watch

In the half year the company has already crossed Net Profit of the previous twelve months

Net Profit (USD MM)

Operating Cash Flow

Highest at USD -6.75 MM

in the last three years

MOJO Watch

The company has generated higher cash revenues from business operations

Operating Cash Flows (USD MM)

EPS

Highest at USD -0.04

in the last five periods

MOJO Watch

Increasing profitability; company has created higher earnings for shareholders

EPS (USD)

Raw Material Cost

Fallen by 0% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Anebulo Pharmaceuticals, Inc.

Interest

At USD 0.3 MM has Grown at 233.08%

over previous Semi-Annual period

MOJO Watch

Rising interest cost signifies increased borrowings

Interest Paid (USD MM)